Vol 4 (April 25, 2026): AME Clinical Trials Review

Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial

Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”

Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward

Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?

Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study

Cachexia, cytokines, and caution: lessons from tocilizumab in advanced pancreatic ductal adenocarcinoma

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial

Not so fast—should neoadjuvant chemotherapy be routine in resectable pancreatic cancers?

Steroid-limited isatuximab-based quadruplet therapy in elderly, transplant-ineligible multiple myeloma: a REST trial commentary

A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers